




# Rezūm™

## Water Vapor Therapy




Transform the BPH treatment experience for your patients with a durable, minimally invasive alternative to medical management

- ▶ First-line therapy option<sup>1</sup>
- ▶ Low retreatment rate<sup>2</sup>
- ▶ Preserves sexual function<sup>3</sup>
- ▶ Doesn't require a permanent implant
- ▶ Able to treat prostates with hyperplasia of the lateral lobes, central zone and/or median lobe
- ▶ Included in 2018 AUA guidelines<sup>4</sup>

### How does the Rezūm System work?

The Rezūm System is a transurethral thermal therapy that uses sterile water vapor (steam) to treat BPH by delivering targeted, controlled doses of thermal energy directly to the prostate gland, targeting and reducing the obstructive tissue that causes BPH.





# Study results show that Rezūm™ Water Vapor Therapy demonstrates durability and significant, sustained BPH symptom relief through 5 years






## Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

In Press: *Urology*, September 2021

Authors: Kevin T. McVary, Claus G. Roehrborn and the Rezūm Clinical Trials Group

The latest published analysis offers evidence that Rezūm Water Vapor Therapy demonstrates significant, sustained improvement of lower urinary tract symptoms (LUTS) and QOL for patients treated for benign prostatic hyperplasia (BPH) through 5 years post-procedure. Improvements as measured by IPSS, QOL, Qmax and BPHII show consistent durability with improvements from initial reporting at 3 months.

### 5-Year Study Data by the Numbers<sup>5,6</sup>

 <b>135 Subjects</b> <b>15 Sites</b>	DURABLE	SUSTAINED RESULTS	
	<b>Surgical Retreatment Rate</b> <b>4.4%</b>	<b>International Prostate Symptom Score (IPSS)</b>  <b>10.4 pts</b> (48%)	<b>Quality of Life Impact (QOL)</b>  <b>2.1 pts</b> (45%)
	<b>Maximum Flow Rate (Qmax)</b>  <b>3.8 mL/sec</b> (44%)	<b>BPH Impact Index (BPHII)</b>  <b>3.4 pts</b> (48%)	

IPSS p-value <.0001 (n=77), QOL p-value <.0001 (n=77), Qmax p-value <.0001 (n=75), BPHI p-value <.0001 (n=77)

In addition to symptom and QOL improvements, surgical retreatment was low, with surgical intervention performed on just 4.4% of subjects through 5 years. Study results show a positive safety profile with preservation of sexual function, and no late-occurring related adverse events or de novo erectile dysfunction reported at 5 years.

**To learn more about Rezūm Water Vapor Therapy or our portfolio of BPH treatment options, contact your Boston Scientific representative**



**When we challenge, we advance.**

- Roehrborn CG, Gange SN, Gittelman MC, et al. Convective water vapor energy (WAVE) ablation therapy: durable two-year results and prospective blinded crossover study for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. *J Urol*. 2017 Jun;197(6):1507-1516
- McVary KT, Roehrborn CG. Three-year outcomes of the prospective, randomized controlled Rezūm system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. *Urology*. 2018 Jan;111:1-9.
- McVary KT, Gange SN, Gittelman MC, et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. *J Urol*. 2016 May;195(5):1529-1538.
- Foster HE, Barry MJ, DahmP, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline. *J Urol*. 2018 Sep;200(3):612-9.
- McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-year outcomes of the multicenter randomized sham-controlled trial of Rezūm water vapor thermal therapy for treatment of moderate-to-severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. *J Urol*. 2021 Sep;206(3):715-24.
- Data on file.

Results from clinical studies are not predictive of results in other studies. Results in other studies may vary.

All images are the property of Boston Scientific. All trademarks are the property of their respective owners.

CAUTION: Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device.

**Boston Scientific**  
Advancing science for life™

Boston Scientific Pty Ltd  
PO Box 332  
Botany NSW 1455 Australia  
Tel: +61 2 8063 8100  
www.bostonscientific.com

© 2022 Boston Scientific Corporation or its affiliates.  
All rights reserved. URO-1266302-AB MAR 2022